Opportunistic muscle measurements on staging chest CT for extremity and truncal soft tissue sarcoma are associated with survival.
Disease-Free Survival
Extremities
/ pathology
Female
Humans
Kaplan-Meier Estimate
Male
Middle Aged
Muscle, Skeletal
/ diagnostic imaging
Neoplasm Staging
Retrospective Studies
Sarcoma
/ diagnostic imaging
Sarcopenia
/ diagnostic imaging
Survival Rate
Tomography, X-Ray Computed
/ methods
Torso
/ pathology
muscle metrics
myosteatosis
sarcoma
sarcopenia
Journal
Journal of surgical oncology
ISSN: 1096-9098
Titre abrégé: J Surg Oncol
Pays: United States
ID NLM: 0222643
Informations de publication
Date de publication:
Oct 2020
Oct 2020
Historique:
received:
04
06
2020
accepted:
10
06
2020
pubmed:
3
7
2020
medline:
13
1
2021
entrez:
3
7
2020
Statut:
ppublish
Résumé
Computed tomography (CT) measurements of sarcopenia have been proposed as biomarkers associated with outcomes in various cancers and have typically been evaluated at the L3 vertebral level. However, staging imaging for patients with extremity and truncal soft tissue sarcoma (STS) often only includes chest CT imaging which precludes evaluation at L3. Therefore, we sought to evaluate muscle metrics at T12 on standard staging chest CT scans and evaluate for correlation with overall and event-free survival in patients with STS. CT chest imaging for 89 patients with intermediate and high-grade STS (53 male, 36 female; 58.5 ± 19.0 years old, follow-up 37.4 ± 27.1 months) was reviewed on PACS at T12 for skeletal muscle density (SMD) and skeletal muscle index (SMI). Overall survival increased with increased SMD on univariate (hazard ratio [HR] = 0.61 [0.43, 0.86]) and age-adjusted analysis (HR = 0.65 [0.42, 0.89]. Event-free survival also increased with increased SMD in univariate analyses (HR = 0.68 [0.49, 0.95]) but did not maintain significance after adjusting for age (HR = 0.68 [0.43, 1.07]). SMI was not a predictor of overall or event-free survival. Higher SMD measured on routinely obtained staging chest CTs in STS patients is associated with improved survival.
Sections du résumé
BACKGROUND AND OBJECTIVES
OBJECTIVE
Computed tomography (CT) measurements of sarcopenia have been proposed as biomarkers associated with outcomes in various cancers and have typically been evaluated at the L3 vertebral level. However, staging imaging for patients with extremity and truncal soft tissue sarcoma (STS) often only includes chest CT imaging which precludes evaluation at L3. Therefore, we sought to evaluate muscle metrics at T12 on standard staging chest CT scans and evaluate for correlation with overall and event-free survival in patients with STS.
METHODS
METHODS
CT chest imaging for 89 patients with intermediate and high-grade STS (53 male, 36 female; 58.5 ± 19.0 years old, follow-up 37.4 ± 27.1 months) was reviewed on PACS at T12 for skeletal muscle density (SMD) and skeletal muscle index (SMI).
RESULTS
RESULTS
Overall survival increased with increased SMD on univariate (hazard ratio [HR] = 0.61 [0.43, 0.86]) and age-adjusted analysis (HR = 0.65 [0.42, 0.89]. Event-free survival also increased with increased SMD in univariate analyses (HR = 0.68 [0.49, 0.95]) but did not maintain significance after adjusting for age (HR = 0.68 [0.43, 1.07]). SMI was not a predictor of overall or event-free survival.
CONCLUSIONS
CONCLUSIONS
Higher SMD measured on routinely obtained staging chest CTs in STS patients is associated with improved survival.
Identifiants
pubmed: 32613648
doi: 10.1002/jso.26077
pmc: PMC8254594
mid: NIHMS1617090
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
869-876Subventions
Organisme : NCATS NIH HHS
ID : UL1 TR001860
Pays : United States
Informations de copyright
© 2020 Wiley Periodicals LLC.
Références
J Urol. 2016 Feb;195(2):270-6
pubmed: 26292038
J Cachexia Sarcopenia Muscle. 2020 Apr;11(2):366-380
pubmed: 31916411
J Cachexia Sarcopenia Muscle. 2016 Dec;7(5):567-576
pubmed: 27104110
Ann Surg Oncol. 2011 Dec;18(13):3579-85
pubmed: 21822551
Clin Cancer Res. 2009 Apr 15;15(8):2920-6
pubmed: 19351764
Ann Surg. 2014 Sep;260(3):416-21; discussion 421-2
pubmed: 25115417
AJR Am J Roentgenol. 2016 Nov;207(5):1046-1054
pubmed: 27556335
Dan Med J. 2014 Nov;61(11):B4957
pubmed: 25370967
Ann Oncol. 2008 May;19 Suppl 2:ii89-93
pubmed: 18456783
Sarcoma. 2015;2015:146481
pubmed: 26696772
Sci Rep. 2018 Jul 27;8(1):11369
pubmed: 30054580
J Gerontol A Biol Sci Med Sci. 2019 Sep 15;74(10):1671-1678
pubmed: 30726878
AJR Am J Roentgenol. 2017 Jun;208(6):W208-W215
pubmed: 28267356
Acad Radiol. 2019 Dec;26(12):1686-1694
pubmed: 31326311
Acad Radiol. 2019 Dec;26(12):1695-1706
pubmed: 31405724
J Surg Oncol. 2020 Jun;121(8):1241-1248
pubmed: 32162343
Acta Radiol. 2018 Apr;59(4):478-484
pubmed: 28747130
J Cancer Surviv. 2012 Dec;6(4):398-406
pubmed: 23054848
Clin Transplant. 2014 Oct;28(10):1092-8
pubmed: 25040933
Dis Esophagus. 2016 Aug;29(6):627-33
pubmed: 26123787
Lancet Oncol. 2008 Jul;9(7):629-35
pubmed: 18539529
Ann Surg Oncol. 2017 Feb;24(2):561-568
pubmed: 27650825
Adv Surg. 2015;49:107-22
pubmed: 26299493
J Am Med Dir Assoc. 2019 Jan;20(1):5-13
pubmed: 30409494
Medicine (Baltimore). 2020 Feb;99(7):e19059
pubmed: 32049805
Eur Radiol. 2016 Dec;26(12):4649-4655
pubmed: 26960539
Br J Surg. 2013 Oct;100(11):1523-30
pubmed: 24037576
J Vasc Surg. 2019 May;69(5):1379-1386
pubmed: 30598352
J Surg Oncol. 2020 Oct;122(5):869-876
pubmed: 32613648
Int J Mol Sci. 2018 Oct 01;19(10):
pubmed: 30275370